

Shionogi Signs Agreement with Denmark on International Industry-Academic Collaboration Initiatives

Osaka, Japan, April 1, 2011- Shionogi & Co., Ltd. (Head Office: Osaka; CEO and Representative Director: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announces that it has entered into an agreement with Kingdom of Denmark (hereafter “Denmark”) on the formation of an international network for industry-academic collaboration in research and development.

The agreement comprises two main undertakings, described below.

1. Matching drug seeds held by Denmark research institutions (including academic institutions and venture companies) with drug-discovery technology and needs of Shionogi, and establishing cooperative research relationships with those institutions by embarking on joint research for drug seeds which meets demands.
2. Personnel exchanges with Denmark research institutions to facilitate international human resources development

Shionogi will continue to expand its network by conducting its SHIONOGI Science Program with academic institutions and venture companies in Denmark.

This agreement with Denmark on international industry-academic collaboration is a cornerstone of Shionogi’s efforts to further accelerate the globalization of its activities.

• Messages from institutional representatives

Franz-Michael Skjold Mellbin, Ambassador from Denmark to Japan

It is a great pleasure for me as Ambassador of Denmark to conclude the Memorandum of Understanding between Shionogi and the Royal Danish Embassy in Tokyo.

Life science, especially bio-pharmaceutical, is one of the important focus areas in Denmark, and Denmark has a very advanced research and development portfolio. Denmark has been the strategic base for establishing new business for emerging technologies as well as a global R&D centre in the field of ICT, energy and environment in addition to life science/biotechnology for a number of European and American companies.

By concluding this Memorandum of Understanding, I hope Shionogi will access Danish competencies in bio-pharmaceutical area from research and development to commercialization more smoothly and find important seeds for their future growth and business expansion.

The Royal Danish Embassy and I would like to strengthen the relationship between Shionogi and Danish companies, universities, hospitals and other relevant organizations.

Isao Teshirogi, Ph.D., CEO and Representative Director, Shionogi & Co., Ltd.

It is a great pleasure for us to sign a contract with Denmark on the formation of an international network for industry-academic collaboration in research and development.

Denmark has Medico Valley, one of the famous bioclusters in Europe and many bio-venture companies as well as academic institutions actively promote research and development on life-science and biotechnology.

We are greatly honored to have an opportunity to form cooperative research relationships and exchange a wide range of information, and also discover drug seeds which we will develop to the medicines making a great contribution to the world. We expect it to foster international human resources by interacting with researchers with cutting-edge knowledge. Taking an advantage of this opportunity, we will accelerate our globalization based on research and development.

SHIONOGI Science Program

SHIONOGI Science Program is a newly collaborative industry-academic initiative to find novel drug seeds globally and develop them for practical use based on Shionogi's constantly effort to provide medicine of the best possible kind essential for protection of the health of the people. Since fiscal 2007, Shionogi has presented its needs under the name of FINDS (PHarma-INnovation Discovery competition Shionogi) and got many innovative ideas from researchers in Japan to put the ideas into the practical use while working together.

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For further information, contact:

Corporate Communications Department

Shionogi & Co., Ltd.

Telephone: +81-6-6209-7885

Fax: +81-6-6229-9596